Navigation Links
Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
Date:2/19/2008

SCOTTSDALE, Ariz., Feb. 19 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.

Lung cancer continues to be the leading worldwide cause of cancer death. Researchers are pursuing a broad array of mechanistic approaches to treatment, including angiogenics/VEGF, EGFR resistance (T790M, MET), HER2 (ErbB2), antifolate, anti-microtubule, apoptosis, Bcl-2/Bcl-xL, TRAIL, vascular disrupting agents, Ras, Raf, MEK, mTOR, PI3, AKT, IGF-1, HSP90, HDAC, JAK/STAT, MAGE-A3, CDK, Aurora Kinase, and anticoagulation.

MedPredict conducted primary, qualitative interviews with renowned US-based Thought Leaders in the areas of non-small cell and small cell lung cancer in order to identify the most promising candidates in clinical development, as well as explore unmet needs. "This report will provide essential strategic insight for those involved in development of lung cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our Thought Leader Panel discusses ongoing clinical programs, and offers their opinions on which of the myriad new drugs in development are likely to be significant improvements over current options."

Some of the companies/partnerships discussed in this report include: Genentech/Roche, Pfizer, AstraZeneca, GlaxoSmithKline, Onyx/Bayer-Schering, Regeneron/Sanofi-Aventis, Genentech/OSI, Imclone/BMS/Merck Serono, Lilly, Exelixis, Wyeth, Boehringer-Ingelheim, Novartis, Mitsubishi/Aveo, Cell Therapeutics, Abbott/Genentech, Genentech/Amgen, Antisoma/Novartis, Antigenics, Concordia, Prolexys, Critical Outcome Technologies, Merck, Schering-Plough, Infinity/Medimmune/AstraZeneca, Synta, Serenex, Bristol Myers Squibb, Abbott, Millennium, Vertex/Merck, Cyclacel.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
4. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
5. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
6. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
7. Michigan Life Sciences Pipeline to Kick Off MichBio Expo
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases
10. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
11. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark ... today the promotion of two long-standing principal investigators (PI) to the roles of ... Research and Development. , Dr. Laurence Chu, a Benchmark Research PI in the ...
Breaking Biology Technology:
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/20/2016)... A market that just keeps on growing. Molecular Diagnostics ... genomics knowledge. Learn all about it in this new ... trends are pushing market growth and company valuations. Trends ... pathogen evolution - next generation sequencing - emergence of ... the role of genetic material in Disease and Health ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):